Skip to main content
Clinical Trials/NCT02336529
NCT02336529
Unknown
Phase 3

Tenderpoint and Ultrasound Guided Nerveblocks for Persistent Pain After Breast Cancer Surgery

Kenneth Geving Andersen0 sites48 target enrollmentJuly 2016

Overview

Phase
Phase 3
Intervention
Bupivacaine
Conditions
Pain
Sponsor
Kenneth Geving Andersen
Enrollment
48
Primary Endpoint
Summed pain intensity
Last Updated
10 years ago

Overview

Brief Summary

Persistent pain after breast cancer surgery (PPBCS) affects 25-60% of breast cancer survivors and nerve damage has been implicated as the cause of this neuropathic pain condition. Local anaesthetic blockade of tenderpoints and the intercostobrachial nerve (ICBN) could provide clues to pathophysiological mechanisms as well as aiding diagnosis and treatment of PPBCS but has never been attempted. The aims of this study is to examine clinical effect of ultrasound guided blockades of the ICBN and tenderpoints of pain.

Registry
clinicaltrials.gov
Start Date
July 2016
End Date
July 2017
Last Updated
10 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Female

Investigators

Sponsor
Kenneth Geving Andersen
Responsible Party
Sponsor Investigator
Principal Investigator

Kenneth Geving Andersen

Research fellow

Rigshospitalet, Denmark

Eligibility Criteria

Inclusion Criteria

  • At least 1 year after surgery for breast cancer
  • Women aged 18 or over
  • Suffering from persistent pain in the breast, side of chest, axilla or arm (NRS 4 or over)

Exclusion Criteria

  • Previous cosmetic surgery
  • bilateral cancer
  • pregnant or lactating
  • other disease in the nervous system
  • in treatment for psychiatric disease
  • unable to understand Danish
  • unable to give informed concent

Arms & Interventions

ICBN, active

Ultrasound guided injection of bupivacain, 10mL, 0.5% in proximity of the ICBN

Intervention: Bupivacaine

ICBN, placebo

Ultrasound guided injection of NaCl, 10mL in proximity of the ICBN

Intervention: NaCl

Tenderpoint, active

Ultrasound guided injection of bupivacain, 20mL, 0.25% in the tenderpoint

Intervention: Bupivacaine

Tenderpoint, placebo

Ultrasound guided injection of NaCl, 20mL in the tenderpoint

Intervention: NaCl

Outcomes

Primary Outcomes

Summed pain intensity

Time Frame: At least 1 year after surgery

The summed pain intensity (of pain at rest (0-10), pain during movement (0-10) and pressure pain (at 100kPa in point of maximum pain) (0-10)) 0-30

Secondary Outcomes

  • Pain at rest, pain during movement and pressure pain(At least 1 year after surgery)
  • Pain related reduction of physical function(At least 1 year after surgery)

Similar Trials